

Product Licence Number	Company Name	Product Name	Active Ingredients	Indications	Date of Authorisation
00101/0481 (continued)	Novartis Pharmaceuticals UK Limited			spondylitis, Acute Gout Control of pain and inflammation in orthopaedic, dental and other minor surgery; Pyrophosphate arthropathy and associated disorders.	
00101/0482	Novartis Pharmaceuticals UK Limited	Voltarol Rapid Tablets 50 mg	Diclofenac Potassium 50.000 mg	Prescription Only Medicine Same as in PL 00101/0481	17th February, 1998
00101/0528	Novartis Pharmaceuticals UK Limited	Lentaron I.M. Depot 250 mg	CGP 32349 (Formestane) HSE 250.0 mg Microcrystalline	Prescription Only Medicine Treatment of advanced breast cancer in women with natural or artificially induced post-menopausal status.	17th November, 1997
00101/0531	Novartis Pharmaceuticals UK Limited	Orimeten Tablets 250 mg	Aminoglutethimide 250.000 mg	Prescription Only Medicine Advanced carcinoma of the breast in post-menopausal or oophorectomised women (especially where the tumours are oestrogen-sensitive), including in particular patients who have previously responded to endocrine therapy or have painful bony metastases. Advanced carcinoma of the prostate as palliative treatment. Subjective improvement and pain relief have been noted in up to 50% of patients. Cushing's syndrome due to malignant disease, e.g. adrenocortical carcinoma or ectopic ACTH syndrome, in place of or in conjunction with surgery.	17th November, 1997
00101/0533	Novartis Pharmaceuticals UK Limited	Prescal Concentrate for Infusion 1 mg/10 ml	Isradipine HSE 1.0 mg	Prescription Only Medicine Treatment of hypertension following coronary surgery.	17th November, 1997
00101/0534	Novartis Pharmaceuticals UK Limited	Prescal LS 1.25 mg	Isradipine HSE 1.25 mg	Prescription Only Medicine Treatment of essential hypertension.	17th November, 1997
00101/0535	Novartis Pharmaceuticals UK Limited	Prescal Retard Capsules 2.5 mg	Isradipine 2.500 mg	Prescription Only Medicine For the treatment of essential hypertension.	17th November, 1997
00101/0536	Novartis Pharmaceuticals UK Limited	Prescal Retard Capsules 5 mg	Isradipine 5.000 mg	Prescription Only Medicine For the treatment of essential hypertension.	17th November, 1997
00101/0537	Novartis Pharmaceuticals UK Limited	Prescal Tablets 2.5 mg	Isradipine, HSE 2.5 mg	Prescription Only Medicine Same as in PL 00101/0534	17th November, 1997
00101/0538	Novartis Pharmaceuticals UK Limited	Prescal Tablets 5 mg	Isradipine HSE 5.0 mg	Prescription Only Medicine Same as in PL 00101/0534	17th November, 1997
00101/0541	Novartis Pharmaceuticals UK Limited	Scopoderm TTS	Drug Reservoir: Scopolamine (Hyoscine) USP 1.31 mg Adhesive (to skin): Scopolamine (Hyoscine) USP 0.23 mg	Prescription Only Medicine For the prevention of symptoms of motion sickness such as nausea, vomiting and vertigo.	17th November, 1997
00101/0542	Novartis Pharmaceuticals UK Limited	Slow-K Tablets 600 mg	Potassium Chloride BP 600 mg	Pharmacy Medicine <i>Recommended clinical Indications, and routes of administration:</i> For the correction and/or prevention of hypokalaemia in those patients who cannot tolerate and/or refuse to take liquid or effervescent potassium chloride, or when there is a problem of compliance with these preparations.	17th November, 1997
00101/0543	Novartis Pharmaceuticals UK Limited	Synacthen Ampoules 250 mcg	Tetracosactrin (as acetate) BP 0.25 mg	Prescription Only Medicine As a diagnostic test for the investigation of adrenocortical insufficiency.	17th November, 1997
00101/0544	Novartis Pharmaceuticals UK Limited	Synacthen Depot Ampoules 1 mg/1 ml	Tetracosactrin (As Acetate) BP 1 mg	Prescription Only Medicine <i>Recommended clinical Indications, and routes of administration:</i> Should normally only be used for short-term therapy in conditions for which Glucocorticoids are indicated in principal, for example, in ulcerative Colitis and Crohn's disease, Juvenile Rheumatoid Arthritis, or as adjunct therapy in patients with Rheumatoid Arthritis and Osteoarthritis. Synacthen depot may be particularly useful in patients unable to tolerate oral Glucocorticoid therapy or in patients where normal therapeutic doses of Glucocorticoids have been ineffective.	17th November, 1997